Here’s Why Arrowhead Pharma (ARWR) Stoch Has Surged Over 45%...

Arrowhead Pharmaceuticals (NASDAQ: ARWR) stock has climbed over 45% higher after the company announced positive interim results from its Phase 2 study of ARO-AAT in treating a rare genetic liver disease.

Arrowhead said that the therapeutic, which is being used in the study to treat a rare genetic liver disease associated with alpha-1 antitrypsin deficiency (AATD), showed clear evidence of a meaningful effect leading to improvements in patients.

“The improvements in additional clinically meaningful biomarkers, including reductions in Z-AAT polymer, improvements in FibroScan values, and decreases in ALT and GGT, were more substantial than we expected,” said Javier San Martin, MD, chief medical officer at Arrowhead.

X testing X

WELCOME BONUS - Free Share Bundle When You Invest £50! Get up to £500 cashback for investing with IG.

Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.

5.0

Open Account Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.

Arrowhead shares…

The news resulted in a leap in Arrowhead’s share price. It closed Wednesday’s trading session at $33.80 and is currently trading at $49.22 per share, up over 45%.

PEOPLE WHO READ THIS ALSO VIEWED: